生物谷原董事长林艳和获刑三年，缓刑请求被驳回 经济观察网 杜远/文 因将上市公司生物谷(920266.BJ)的资金违规违法转至深圳金沙江投资有限公司(下称"金沙江投资")，生 物谷原实际控制人、董事长林艳和获刑三年，二审法院驳回了缓刑请求。 12月22日晚，生物谷公告披露，林艳和原系生物谷法定代表人和实际控制人，时任生物谷董事长兼总经 理，同时亦是金沙江投资的实际控制人。为满足金沙江投资资金需求，2021年8月27日至2022年3月11 日，林艳和安排时任生物谷董事会秘书兼财务总监贺元，违反上市公司财务管理制度、未在生物谷按规 定召开总经理办公会和未经公司投资评审小组审议的情况下，隐瞒资金真实用途，利用生物谷投资理财 决议，虚构委托第三方机构理财的事实，将生物谷及子公司的自有资金转至多家外部公司， 2020年7月，精选层敲钟开市，首批32家企业晋层交易。时任生物谷董事长林艳和在媒体上发出"寄 语"："精选层将是中国价值创新、价值创造中不可缺少的一个内核。生物谷也将为精选层、为我国资本 市场中国价值的展现，点亮一束光，贡献一份热。" 然而，不到两年后情势直转。2022年5月11日，林艳和因涉嫌信息披露违法违规被 ...

第 781 期 2025-12-23 焦点事件 罕见！上市公司董事会拒绝大股东五项临时提案 华夏幸福公告，董事会拒绝股东平安人寿增加五项临时提案至股东大会。根据公告，平安人寿提议新增5项临时提案，提交华夏幸福2025年第三次临时股东 大会审议。 12月21日，华夏幸福召开第八届董事会第三十六次会议，审议上述议案，最终以1票同意、7票反对、0票弃权的投票结果，未通过公司董事会审议。 生物谷公告，收到云南省高院《刑事裁定书》，公司原实际控制人，原董事长兼总经理林艳和、原董事会秘书兼财务总监贺元犯背信损害上市公司利益罪， 林艳和被判处有期徒刑3年，并处罚金500万元，贺元被判有期徒刑一年六个月，并处罚金200万元。冻结在案的人民币6200万元发还生物谷，继续追缴被告 人林艳和违法所得退赔生物谷。 沪深北交易所发布！2026年A股休市安排来了 沪深北交易所发布2026年部分节假日休市安排。 （一）元旦：1月1日至1月3日休市，1月5日起照常开市。另外，1月4日为周末休市。（二）春节：2月15日至2月23日休市，2月24日起照常开市。另外，2月 14日、2月28日为周末休市。（三）清明节：4月4日至4月6日休市，4月7 ...

Core Points - Yunnan Biotech Pharmaceutical Co., Ltd. (referred to as "Biotech") announced that the Yunnan Provincial High People's Court upheld the original ruling, sentencing former actual controller Lin Yanhe to three years in prison and a fine of 5 million yuan, while former CFO He Yuan received a sentence of one and a half years and a fine of 2 million yuan [1] - The case involved Lin Yanhe and He Yuan misappropriating company funds for personal financial needs, leading to administrative penalties from the China Securities Regulatory Commission (CSRC) and subsequent criminal charges [1][2] - The CSRC has been actively enforcing strict regulations against financial misconduct, emphasizing the protection of small investors and the integrity of innovative small and medium-sized enterprises [2] Company Overview - Biotech was established in 1999 and focuses on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system [1] - The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [1] Legal Proceedings - The case against Lin Yanhe and He Yuan for breaching fiduciary duties was heard in Kunming Intermediate People's Court, resulting in a conviction and financial penalties, with the court ordering the return of misappropriated funds to Biotech [2] - The Yunnan Securities Regulatory Bureau initiated an investigation into the misconduct, leading to significant administrative penalties and a referral for criminal prosecution [1][2]

Core Viewpoint - Yunnan Biological Valley Pharmaceutical Co., Ltd. has faced legal consequences for financial misconduct involving its former actual controller and financial director, highlighting the regulatory environment's strict stance against such violations [2][3]. Company Summary - Yunnan Biological Valley was established in 1999, focusing on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system drugs. The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [2]. - The former actual controller, Lin Yanhua, and the former financial director, He Yuan, were found guilty of misappropriating company funds for personal financial needs, leading to their convictions and sentences [2][3]. Regulatory Actions - In May 2022, the Yunnan Securities Regulatory Bureau initiated an investigation into the illegal activities, resulting in administrative penalties of 5 million yuan for Lin Yanhua and 2 million yuan for He Yuan, along with market entry bans [3]. - The case reflects the China Securities Regulatory Commission's commitment to combating financial misconduct and protecting the rights of small investors, emphasizing a zero-tolerance policy towards fund misappropriation [3].

生物谷（920266）12月3日大宗交易平台出现一笔成交，成交量10.00万股，成交金额70.00万元，大宗交 易成交价为7.00元，相对今日收盘价折价26.32%。该笔交易的买方营业部为中国银河证券股份有限公司 佛山绿景一路证券营业部，卖方营业部为国新证券股份有限公司昆明拓东路证券营业部。 据天眼查APP显示，云南生物谷药业股份有限公司成立于1999年06月13日，注册资本12400.0007万人民 币。（数据宝） 12月3日生物谷大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | | | | | 中国银河证券股份有限公 | 国新证券股份有限公 | | 10.00 | 70.00 | 7.00 | -26.32 | 司佛山绿景一路证券营业 | 司昆明拓东路证券营 | | | | | | 部 | 业部 | （文章来源：证券时报网） 进一步统计，近1个月内该股累计发生2笔大宗交易，合计成交金额为190.0 ...

证券日报网讯12月2日晚间，生物谷发布公告称，截至2025年11月28日，公司已通过集中竞价交易方式 累计出售回购股份527，630股，占公司总股本的比例为0.43%，成交总额为5，098，846.83元(未扣除交 易费用、税金)，成交最高价为10.11元/股，最低价为9.34元/股，均价为9.66元/股。 ...

Core Viewpoint - A block trade of 150,000 shares of Yunnan Biovalley Pharmaceutical Co., Ltd. was executed on November 5, with a transaction price of 8.00 yuan, representing a discount of 25.02% compared to the closing price of 10.67 yuan on the same day [2] Group 1: Trade Details - The transaction volume was 150,000 shares, with a total transaction value of 1.2 million yuan [2] - The buyer was Guotou Securities Co., Ltd. Meizhou Fengshun Securities Branch, while the seller was Guoxin Securities Co., Ltd. Kunming Tuodong Road Securities Branch [2] - The closing price of Yunnan Biovalley on November 5 was 10.67 yuan, reflecting an increase of 1.43% with a turnover rate of 2.50% and a total trading volume of 21.45 million yuan for the day [2] Group 2: Company Background - Yunnan Biovalley Pharmaceutical Co., Ltd. was established on June 13, 1999, with a registered capital of 1.24 billion yuan [2]

Core Insights - The article highlights the development of a billion-level "Northern Bio Valley" in Dezhou, focusing on the growth of the biotechnology industry through collaboration and innovation [1][2][4] Industry Overview - Dezhou is concentrating on five key areas within the biotechnology sector: biomanufacturing, biomedicine, bio-agriculture, biomedical engineering, and biomass energy, aiming for high-end, clustered, and international development [2][3] - The city has established a clear framework for its biotechnology industry, with 153 enterprises in the sector and projected revenue of 40.4 billion yuan in 2024 [2] Innovation and Collaboration - Innovation is identified as the core driver for overcoming challenges and seizing development opportunities, supported by numerous national and provincial innovation platforms [3] - Dezhou has established long-term collaborations with over 40 universities and research institutions, holding nearly 300 patents related to biopreparation [3] Regional Development - Different regions within Dezhou are focusing on specific areas of biotechnology, such as biomanufacturing in Yucheng and medical devices in Qihe, creating a diverse and collaborative development landscape [4] - The city has mechanisms in place for regular roadshows and result transformation, targeting investors, entrepreneurs, and industry experts to facilitate efficient connections among technology, capital, market, and policy [4] Future Outlook - Dezhou aims to target cutting-edge fields such as synthetic biology, gene cell therapy, and AI pharmaceuticals, with plans to establish high-level innovation platforms and pilot bases [4] - The city is committed to enhancing its industrial cluster development, optimizing its industrial layout, and attracting leading enterprises and major projects to achieve the goal of becoming a billion-level "Northern Bio Valley" [4]

Core Insights - The article discusses the development of a billion-level "Northern Bio Valley" in Dezhou, focusing on the growth and innovation in the biotechnology industry [1][3][6] Industry Overview - Dezhou is concentrating on five key areas within the biotechnology sector: biomanufacturing, biopharmaceuticals, bio-agriculture, biomedical engineering, and biomass energy [3] - The city has established a clear layout and strong innovation initiatives to promote high-end, clustered, and international development of the industry [3] Current Developments - The biomanufacturing industry in Dezhou has seen significant growth, with 153 enterprises in the sector and projected revenue of 40.4 billion yuan in 2024 [3] - Eight companies in the biotechnology sector have achieved over 1 billion yuan in output value, while 41 companies have surpassed 100 million yuan [3] Innovation and Collaboration - Innovation is identified as the core driver for overcoming challenges and seizing development opportunities in the biotechnology industry [4] - Dezhou has established numerous national and provincial innovation platforms and maintains long-term collaborations with over 40 universities and research institutions [4] Product Development - Companies like Baolingbao Biological Co., Ltd. are developing new products such as erythritol, with a production capacity of 30,000 tons per year, and exporting to over 70 countries [4] Strategic Initiatives - Dezhou is implementing mechanisms for regular roadshows and results transformation to connect investors, entrepreneurs, and industry experts [5] - The city is also exploring the establishment of a specialized fund for the biotechnology industry and has formed an association for high-quality development in the sector [5] Future Outlook - Dezhou aims to focus on cutting-edge areas such as synthetic biology, gene cell therapy, and AI pharmaceuticals, while continuing to optimize its industrial layout and attract leading enterprises [6]

Core Viewpoint - The company Biotech Valley (920266.BJ) announced the sale of 762,514 shares that were repurchased in 2022, which represents 0.61% of its total share capital. The proceeds from this sale will be used to supplement the company's working capital [1]. Group 1 - The company will hold its fifth board meeting on October 20, 2025, to review the proposal for selling the repurchased shares [1]. - The sale period for the repurchased shares will begin 15 trading days after the announcement and will last until December 8, 2025, with restrictions during any periods prohibited by the China Securities Regulatory Commission and the Beijing Stock Exchange [1]. - The selling price of the shares will be determined based on the market price at the time of sale, with a stipulation that the declared price cannot be lower than the daily trading limit [1]. Group 2 - Biotech Valley was listed on the Beijing Stock Exchange on November 15, 2021, becoming the first company from Yunnan to be listed there [3]. - The company previously went public on July 27, 2020, on the National Equities Exchange and Quotations (NEEQ) with an issuance of 6.849 million shares at a price of 13.99 yuan per share, raising a total of approximately 95.82 million yuan [2].